Crossmark

TRF1 and TRF2: pioneering targets in telomere-based cancer therapy

Crossref DOI link: https://doi.org/10.1007/s00432-024-05867-3

Published Online: 2024-07-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kallingal, Anoop https://orcid.org/0000-0002-9613-3259
Krzemieniecki, Radosław https://orcid.org/0000-0002-3248-2193
Maciejewska, Natalia https://orcid.org/0000-0001-9942-285X
Brankiewicz-Kopcińska, Wioletta https://orcid.org/0000-0002-8314-0775
Baginski, Maciej https://orcid.org/0000-0002-6795-7515
License Information

Text and Data Mining valid from 2024-07-16

Version of Record valid from 2024-07-16
More Information

Article History

Received: 30 April 2024

Accepted: 25 June 2024

First Online: 16 July 2024

Declarations

:

: The authors declare that they have no conflicts of interest.